Vivo Capital VIII, LLC

This profile gathers the share dealings of Vivo Capital VIII, LLC across 8 companies, led by Crinetics Pharmaceuticals, Inc., Bolt Biotherapeutics, Inc. and Impel Neuropharma Inc. Between 18 September 2017 and 15 December 2023, the trades on record add up to 99 filings.

Both buying and selling appear: 18 purchases worth €36.7M, against 43 sales worth €18.8M. Purchases outweigh sales by €17.9M. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Outside the open market, there are 3 share grants. 2023 to date brings no purchases and 3 sales.

A typical purchase (the median) is worth €1.2M. Clusters matter here: 8 out of 10 purchases overlapped with buying by a colleague within 30 days. Purchases made close together by different insiders form what is called a cluster. For 4 purchases whose 90-day window has closed, the share price was higher on day 90 than the day after publication in 50% of cases, with a median move of +15.7%. They describe history only and say nothing certain about the share price ahead.

The record was last updated on 19 December 2023 with an open-market sale (€23k) in Impel Neuropharma Inc. The latest purchase dates back some time: it was published 2,003 days ago, on 29 April 2021. The median gap between trade and publication is zero days: most filings appear on the same day. The legal deadline for a Form 4 is two business days after the transaction. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.